Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2015-12-01
|
| Series: | Journal of Pharmaceutical Policy and Practice |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1186/2052-3211-8-S1-O13 |
| _version_ | 1797327260109242368 |
|---|---|
| author | Hedi Schelleman Rudy Dupree Finn B Kristensen Wim Goettsch |
| author_facet | Hedi Schelleman Rudy Dupree Finn B Kristensen Wim Goettsch |
| author_sort | Hedi Schelleman |
| collection | DOAJ |
| first_indexed | 2024-03-08T06:35:43Z |
| format | Article |
| id | doaj.art-caba7b54d56a44e0b4c7d5d3e8a18660 |
| institution | Directory Open Access Journal |
| issn | 2052-3211 |
| language | English |
| last_indexed | 2024-03-08T06:35:43Z |
| publishDate | 2015-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Pharmaceutical Policy and Practice |
| spelling | doaj.art-caba7b54d56a44e0b4c7d5d3e8a186602024-02-03T10:20:36ZengTaylor & Francis GroupJournal of Pharmaceutical Policy and Practice2052-32112015-12-018sup110.1186/2052-3211-8-S1-O13Why we should have more collaboration on HTA in Europe: the example of sofosbuvirHedi Schelleman0Rudy Dupree1Finn B Kristensen2Wim Goettsch3National health Care Institute, Diemen Zuid, 1112 XH, the Netherlands.National health Care Institute, Diemen Zuid, 1112 XH, the Netherlands.University of Southern Denmark, Copenhagen, 1399, Denmark.National health Care Institute, Diemen Zuid, 1112 XH, the Netherlands.https://www.tandfonline.com/doi/10.1186/2052-3211-8-S1-O13Health Technology AssessmentSuccess FactorEastern European CountrySofosbuvirPromising Agent |
| spellingShingle | Hedi Schelleman Rudy Dupree Finn B Kristensen Wim Goettsch Why we should have more collaboration on HTA in Europe: the example of sofosbuvir Journal of Pharmaceutical Policy and Practice Health Technology Assessment Success Factor Eastern European Country Sofosbuvir Promising Agent |
| title | Why we should have more collaboration on HTA in Europe: the example of sofosbuvir |
| title_full | Why we should have more collaboration on HTA in Europe: the example of sofosbuvir |
| title_fullStr | Why we should have more collaboration on HTA in Europe: the example of sofosbuvir |
| title_full_unstemmed | Why we should have more collaboration on HTA in Europe: the example of sofosbuvir |
| title_short | Why we should have more collaboration on HTA in Europe: the example of sofosbuvir |
| title_sort | why we should have more collaboration on hta in europe the example of sofosbuvir |
| topic | Health Technology Assessment Success Factor Eastern European Country Sofosbuvir Promising Agent |
| url | https://www.tandfonline.com/doi/10.1186/2052-3211-8-S1-O13 |
| work_keys_str_mv | AT hedischelleman whyweshouldhavemorecollaborationonhtaineuropetheexampleofsofosbuvir AT rudydupree whyweshouldhavemorecollaborationonhtaineuropetheexampleofsofosbuvir AT finnbkristensen whyweshouldhavemorecollaborationonhtaineuropetheexampleofsofosbuvir AT wimgoettsch whyweshouldhavemorecollaborationonhtaineuropetheexampleofsofosbuvir |